Provided by Tiger Trade Technology Pte. Ltd.

Edgewise Therapeutics, Inc.

44.21
-0.5100-1.14%
Post-market: 44.210.00000.00%19:30 EDT
Volume:1.15M
Turnover:51.47M
Market Cap:4.80B
PE:-23.90
High:46.32
Open:45.22
Low:44.02
Close:44.72
52wk High:48.40
52wk Low:13.69
Shares:108.60M
Float Shares:88.17M
Volume Ratio:0.78
T/O Rate:1.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8502
EPS(LYR):-1.6302
ROE:-38.03%
ROA:-25.03%
PB:10.72
PE(LYR):-27.12

Loading ...

Edgewise Therapeutics Files Amended 8-K with Unaudited Pro Forma Financials for Servier Asset Sale

Reuters
·
Jul 16

Edgewise Therapeutics Sells Muscular Dystrophy Assets to Servier

TIPRANKS
·
Jul 14

Edgewise Therapeutics Sells Sevasemten, Muscular Dystrophy Business to Servier for up to $2.65 Billion

Reuters
·
Jul 13

Edgewise Therapeutics completes sale of sevasemten for up to $2.65B

TIPRANKS
·
Jul 13

Edgewise Therapeutics expects to initiate Phase 3 trial of EDG-7500 in Q4

TIPRANKS
·
Jul 13

Edgewise Therapeutics Completes Sale of Sevasemten for up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

THOMSON REUTERS
·
Jul 13

Edgewise Therapeutics' EDG-7500 Seen Entering 'Catalyst-Dense' Regulatory Period, Oppenheimer Says

MT Newswires Live
·
Jul 09

Oppenheimer Initiates Edgewise Therapeutics at Outperform

MT Newswires Live
·
Jul 09

Edgewise Therapeutics initiated with an Outperform at Oppenheimer

TIPRANKS
·
Jul 09

Edgewise Therapeutics is Maintained at Buy by Guggenheim

Dow Jones
·
Jul 06

Edgewise Therapeutics price target raised to $51 from $41 at Guggenheim

TIPRANKS
·
Jul 06

Top Edgewise Therapeutics Executive Makes Major Move With Insider Stock Sale

TIPRANKS
·
Jul 03

Edgewise Therapeutics CSO Alan J. Russell Sells 200,000 Common Shares Worth $7.88 Million

Reuters
·
Jul 03

Edgewise Therapeutics Grants Inducement Stock Options for 16,500 Shares at $40.63 Each

Reuters
·
Jul 01

Edgewise Therapeutics Reports Inducement Grants as Permitted by the NASDAQ Listing Rules

THOMSON REUTERS
·
Jul 01

Why Edgewise Therapeutics (EWTX) Is Up 13.3% After Phase 2 EDG-7500 HCM Data Release

Simply Wall St.
·
Jun 26

Edgewise Therapeutics Remains Compelling Cardiology Story Despite Atrial Fibrillation Concerns, RBC Says

MT Newswires Live
·
Jun 17

Edgewise Therapeutics Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
Jun 17

RBC Raises Price Target on Edgewise Therapeutics to $59 From $48, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jun 17

Edgewise Therapeutics price target raised to $32 from $20 at Goldman Sachs

TIPRANKS
·
Jun 17